You are here

Article info

Article menu
XML
Immune cell therapies and immune cell engineering
Original research
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

Authors

  • John E Levine Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, Michigan, USATisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles
  • Stephan A Grupp Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USADivision of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Michael A Pulsipher Section of Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, University of Southern California Keck School of Medicine, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Andrew C Dietz Section of Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, University of Southern California Keck School of Medicine, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Susana Rives Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu de Barcelona, Barcelona, SpainInstitut de Recerca Sant Joan de Déu, Barcelona, Spain PubMed articlesGoogle scholar articles
  • G Douglas Myers Children’s Mercy Hospital Kansas City, Kansas City, Missouri, USA PubMed articlesGoogle scholar articles
  • Keith J August Children’s Mercy Hospital Kansas City, Kansas City, Missouri, USA PubMed articlesGoogle scholar articles
  • Michael R Verneris Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis, Minnesota, USADepartment of BMT and Cellular Therapy, Children’s Hospital Colorado, University of Colorado, Boulder, Colorado, USA PubMed articlesGoogle scholar articles
  • Jochen Buechner Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway PubMed articlesGoogle scholar articles
  • Theodore W Laetsch Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USADivision of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USADepartment of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USAPauline Allen Gill Center for Cancer and Blood Disorders, Children’s Health, Dallas, Texas, USA PubMed articlesGoogle scholar articles
  • Henrique Bittencourt Hematology Oncology Division, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, Québec, CanadaDepartment of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Québec, Canada PubMed articlesGoogle scholar articles
  • Andre Baruchel Pediatric Hematology-Immunology Department, University Hospital Robert Debré (APHP) and Université de Paris, Paris, France PubMed articlesGoogle scholar articles
  • Michael W Boyer Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, Utah, USA PubMed articlesGoogle scholar articles
  • Barbara De Moerloose Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, BelgiumCancer Research Institute Ghent (CRIG), Ghent, Belgium PubMed articlesGoogle scholar articles
  • Muna Qayed Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Stella M Davies Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USACancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA PubMed articlesGoogle scholar articles
  • Christine L Phillips Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USACancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA PubMed articlesGoogle scholar articles
  • Timothy A Driscoll Department of Pediatric Transplant and Cellular Therapy, Children’s Health Center, Duke University Medical Center, Durham, North Carolina, USA PubMed articlesGoogle scholar articles
  • Peter Bader Division for Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany PubMed articlesGoogle scholar articles
  • Krysta Schlis Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA PubMed articlesGoogle scholar articles
  • Patricia A Wood Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA PubMed articlesGoogle scholar articles
  • Rajen Mody Department of Pediatrics, Division of Pediatric Hematology Oncology, Michigan Medicine, Ann Arbor, Michigan, USA PubMed articlesGoogle scholar articles
  • Lan Yi Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA PubMed articlesGoogle scholar articles
  • Mimi Leung Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA PubMed articlesGoogle scholar articles
  • Lamis K Eldjerou Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA PubMed articlesGoogle scholar articles
  • Carl H June Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USADepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Shannon L Maude Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USADivision of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Shannon L Maude; maude{at}chop.edu
View Full Text

Citation

Levine JE, Grupp SA, Pulsipher MA, et al
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
Journal for ImmunoTherapy of Cancer 2021;9:e002287. doi: 10.1136/jitc-2020-002287

Publication history

  • Accepted June 10, 2021
  • First published August 5, 2021.
Online issue publication 
November 02, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.